Should I Buy OPK? OPK 2026 Analysis

Should You Buy OPKO Health Inc (OPK) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.270

1 Day change

-0.78%

52 Week Range

2.040

Analysis Updated At

2026/01/26

OPKO Health Inc (OPK) is not a strong buy at the moment for a beginner investor with a long-term strategy. The company has a declining financial performance, lacks significant positive catalysts, and its stock price trend is neutral to slightly bearish. While hedge funds and insiders are buying, the lack of clear clinical validation for its pipeline and the absence of strong trading signals make it prudent to hold off on investing right now.

Technical Analysis

The MACD histogram is slightly positive at 0.00408, but it is contracting, showing no strong upward momentum. RSI is neutral at 48.298, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 1.266), with resistance at 1.335 and 1.403. Overall, the technical indicators suggest a neutral to slightly bearish trend.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate a bullish sentiment among options traders, but the overall trading volume is not significant enough to drive a strong directional bias.

Technical Summary

Sell

Buy

Positive Catalysts

Hedge funds and insiders are significantly increasing their buying activity, which could indicate confidence in the company's future. Gross margin has improved significantly, up 76.54% YoY.

Neutral/Negative Catalysts

Revenue, net income, and EPS have all declined YoY in the latest quarter. Analysts have downgraded the stock, citing the early-stage nature of its drug pipeline and lack of clinical validation. No recent news or significant events to act as a catalyst for growth.

Financial Performance

In Q3 2025, revenue dropped by 12.65% YoY to $151.67 million, net income fell by 13.09% YoY to $21.63 million, and EPS declined by 25% YoY to $0.03. However, gross margin improved significantly to 20.02%, up 76.54% YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are cautious about OPKO Health. JPMorgan initiated coverage with a Neutral rating, citing the need for clinical validation. Jefferies downgraded the stock from Buy to Hold, reducing the price target from $2 to $1.60, reflecting concerns over the clarity of catalysts and the early-stage pipeline.

3 Analyst Rating

Wall Street analysts forecast OPK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OPK is 2.75 USD with a low forecast of 2.25 USD and a high forecast of 3 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.280

Low

2.25

Averages

2.75

High

Current: 1.280

Low

2.25

Averages

2.75

High

JPMorgan

Neutral

initiated

AI Analysis

2025-11-20

Reason

JPMorgan

Price Target

AI Analysis

2025-11-20

initiated

Neutral

Reason

JPMorgan initiated coverage of Opko Health with a Neutral rating and no price target. The firm says Opko is a "multi-faceted" healthcare company, focusing in clinical diagnostics services through BioReference Labs operations and therapeutics development through its ModeX subsidiary. The company's clinical-stage pipeline portfolio remains early stage and needs clinical validation before "buy-in from investors," the analyst tells investors in a research note. JPMorgan awaits clinical validation before recommending the shares.

Jefferies

Buy

Hold

downgrade

2025-10-30

Reason

Jefferies

Price Target

2025-10-30

downgrade

Buy

Hold

Reason

Jefferies downgraded Opko Health to Hold from Buy with a price target of $1.60, down from $2. The firm, which is lowering Ngenla out-year estimates, says Opko's drug pipeline has potential, but is still early with a need for clarity on catalysts.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for OPK

Unlock Now

OPK Should I Buy

OPK Should I Buy

Should You Buy OPKO Health Inc (OPK) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch